Journal
CLINICAL MICROBIOLOGY AND INFECTION
Volume 9, Issue 6, Pages 475-488Publisher
ELSEVIER SCI LTD
DOI: 10.1046/j.1469-0691.2003.00674.x
Keywords
Bacteroides fragilis group; antimicrobial resistance; beta-lactams; clindamycin; metronidazole; moxifloxacin
Categories
Ask authors/readers for more resources
Objective To evaluate the activity of old and newer antianaerobic drugs against clinical isolates of Bacteroides fragilis group strains from different parts of Europe. Methods Bacteroides fragilis group isolates from 37 laboratories in 19 countries were biochemically characterized. The MICs of seven antimicrobial agents were determined by the agar dilution method as recommended by the NCCLS. Production of beta-lactamase was detected by nitrocefin. Results There were 1284 B. fragilis group isolates included in the study. Abdominal infections and wounds were the most common sources of isolation and B. fragilis was the dominating species. Ninety-nine percent of the strains were resistant to ampicillin (breakpoint 2 mg/L), 6% to cefoxitin (64 mg/L), 15% to clindamycin (8 mg/L) and 9% to moxifloxacin (8 mg/L). Less than 1% were resistant to imipenem (16 mg/L), piperacillin-tazobactam (128 mg/L) and metronidazole (32 mg/L). Ninety-six percent of the isolates were beta-lactamase producers. Conclusion Antimicrobial resistance among the B. fragilis group is increasing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available